Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $57.50.

Several research firms recently weighed in on COLL. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Needham & Company LLC restated a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in COLL. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after acquiring an additional 538,337 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Collegium Pharmaceutical by 65.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after buying an additional 518,721 shares in the last quarter. Millennium Management LLC raised its stake in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after buying an additional 461,914 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Collegium Pharmaceutical by 161.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock worth $23,692,000 after buying an additional 316,109 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Collegium Pharmaceutical by 897.2% in the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock worth $9,423,000 after acquiring an additional 242,310 shares in the last quarter.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL remained flat at $37.03 during midday trading on Friday. The stock had a trading volume of 480,480 shares, compared to its average volume of 425,763. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical has a fifty-two week low of $29.19 and a fifty-two week high of $50.79. The company has a market cap of $1.20 billion, a P/E ratio of 18.15 and a beta of 0.73. The business has a fifty day moving average of $34.36 and a two-hundred day moving average of $39.26.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the prior year, the company earned $1.49 EPS. The company’s revenue was up 8.9% on a year-over-year basis. On average, research analysts forecast that Collegium Pharmaceutical will post 6.76 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.